Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
InFlectis BioScience
InFlectis BioScience is developing small molecule drugs that target the Integrated Stress Response to treat various diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novel molecule using a new Mode of Action to treat and prevent atrial fibrillation.
Sector
Subsector
Keywords
Location
total rounds
total raised
Frequency Therapeutics
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.
Sector
Subsector
Keywords
Location
total rounds
total raised
RemAb Therapeutics
RemAb Therapeutics develops polymeric glycoconjugates to treat nosocomial infections.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 14.06.2023. Their latest investor JobsOhio Growth Capital Fund. Their latest round Series B
CincyTech
CincyTech is a venture capital firm that helps transform innovation into high-growth life science and digital companies in Southwest Ohio.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors4
Number of lead investors
Number of investors
JobsOhio Growth Capital Fund
JOGC invests in early-stage venture-backed companies in Ohio.
Sector
Subsector
Keywords
count Of Investments
count Of Exists
Jumpstart Ventures
Jumpstart Ventures is a Chicago-based venture capital firm that invests in early-stage startups.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Rev1 Ventures
Rev1 Ventures is a Midwest-based investor startup studio that provides capital and strategic services.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Ryan Helon
Ryan J. Helon serves as Senior Vice President, Investments at TechColumbus, Investment Arm. Mr. Helon serves as Managing Director at Nationwide Mutual Capital. He leads Nationwide Mutual, including originating, executing, and managing investments. He also develops and implements strategies for Nationwide Mutual to leverage the resources of Nationwide to add value to Nationwide Mutual Capital portfolio companies. He also leads strategy development for Nationwide Mutual. Prior to his leadership role with Nationwide Mutual, Mr. Helon served as a Corporate Development Manager at Nationwide, where he led and participated in many transactions, including the CalFarm and Marítima acquisitions, the private equity investments in Teamstaff and Capital Professional Advisors and Nationwide Mutual's $400 million issuance of surplus notes. Mr. Helon also jointly led the creation and development of the firm. Prior to Nationwide, he worked in corporate finance in the chemical industry, primarily on M&A transactions. Mr. Helon serves on the Boards at First Choice Solutions, Skybus, and The Columbus Council on World Affairs. Mr. Helon received an M.B.A. from The Ohio State University Fisher College of Business, where he graduated as salutatorian and graduated with a Bachelor's degree in Finance and Economics, summa cum laude, also from The Ohio State University Fisher College of Business.
current job
People
Founders1
Robert Shalwitz
Robert Shalwitz co-founded Akebia in 2007 and is continuing on as Chief Medical Officer at Aerpio. He has principal responsibility for the development of AKB-4924. During the last 5 years with Akebia, Robert Shalwitz brought AKB-6548 into Phase 2b for anemia. He was also very involved in the development of AKB-9778 for vascular leak, and bringing in federal and state grants to support the wound healing program for AKB-4924. Prior to Akebia, Robert Shalwitz was Vice President of Clinical Development at Reliant Pharmaceuticals, where he led a clinical team which launched and completed numerous clinical trials for the treatment of lipid and cardiac disorders, and contributed to several FDA filings. Before Reliant, Robert Shalwitz was Medical Director at Abbott Labs. During his 10-year tenure at Abbott Labs, Robert Shalwitz team gained FDA approval for two NDAs (in lipid and cardiac disease). In addition, he acquired experience in all phases of drug development, from preclinical to Phase 4. Complementing his work in clinical development, Robert Shalwitz became very experienced in pharmaco-vigilance and post-marketing medical affairs. Before Abbott Labs, Dr. Shalwitz was an academic pediatric endocrinologist for 10 years. His research at Washington University in St. Louis and at the Children's Hospital of Orange County (CA) focused on glucose and glycogen metabolism. Dr. Shalwitz received an M.D. degree from SUNY Buffalo and a BGS degree from the University of Michigan.
current job
organization founded
Robert Shalwitz